Access and Evidence
How to synthesise real-world evidence and AI to transform patient-driven healthcare
Pharmaceutical companies have more real-world data (RWD) than ever. As health records have gone digital, sensors have enabled...
Access and Evidence
Cell and gene therapy: how to discover and communicate clinical worth
Watch the full webinar here. Market access is more complex than ever. It requires a delicate balance of demonstrating value to payers...
Latest
-
Access and EvidenceCGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach.
-
Access and Evidence
What not to miss on Cell and Gene Therapy stage at Reuters Events: Pharma USA 2024
From building a solid value proposition to innovating through collaboration, discover where industry changemakers see the strengths of cell and gene in 2024. -
Medical
Cell and gene therapy: ways to generate evidence to demonstrate value
Although cell and gene therapies (CGTs) are typically expensive products, there are techniques that pharmaceutical companies can execute to underscore why they are worthwhile. -
Multichannel
How pharma is empowering key account managers to serve a changing customer base
Key account management (KAM) has become increasingly important to pharma companies as payers and other stakeholders have begun to exert more influence over the products physicians prescribe -
Medical
Diversity in clinical trials requires a multifaceted approach
Clinical trial sponsors should implement multiple approaches to boost diversity in studies, from ensuring collected data reflect participant diversity, to working with a diverse group of investigators
Most Popular
Lucy Fulford, (Mar 20, 2024)
From building a solid value proposition to innovating through collaboration, discover where industry changemakers see the strengths of cell and gene in 2024.
Anonymous (not verified), (Mar 22, 2024)
CGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach.
Commercial
-
Omnichannel: Getting it right
Success with omnichannel depends on having the right customer data, analytics, and software. -
Omnichannel strategy: a valuable data source for customer profile generation
An omnichannel approach allows pharma companies to meet customer needs in a targeted way according to any customer’s preferred communication medium. -
How pharma leaders expedite market access with cutting edge value frameworks
Pharma seeks swift market access for innovative treatments amid evolving regulations, emphasizing collaboration and proactive planning for timely delivery of life-changing therapies. -
Medical affairs: judicious analysis essential amid large datasets
With the increased use of healthcare technologies, leading to record volumes of data, pharma need to be strategic in extracting insights to drive their marketing strategy. -
Using data to upgrade patient journeys
Collecting and analyzing patient data can improve all aspects of a patient’s health journey. Data privacy must never be compromised in the process.
Multichannel
-
How pharma is empowering key account managers to serve a changing customer base
Key account management (KAM) has become increasingly important to pharma companies as payers and other stakeholders have begun to exert more influence over the products physicians prescribe -
Using data to upgrade patient journeys
Collecting and analyzing patient data can improve all aspects of a patient’s health journey. Data privacy must never be compromised in the process. -
Driving next best actions using timely data insights
The omnichannel era presents new opportunities for pharma to more effectively engage with its customers by identifying next best actions (NBAs) driven by more relevant and timely data insights. -
Meet information demands through modular content
Adopting a modular content strategy allows pharmaceutical companies to reuse and adapt information, speeding up content creation cycles without risking personalization. -
The patient, AI and the search for answers
AI-powered chat that looks set to upend the patient search experience online is both threat and opportunity for pharma
Access and Evidence
-
Cell and gene therapy: how to discover and communicate clinical worth
CGTs are often expensive, and the healthcare sector is increasingly working on a tight budget. To bolster CGT market access potential, pharma companies should take a holistic approach. -
What not to miss on Cell and Gene Therapy stage at Reuters Events: Pharma USA 2024
From building a solid value proposition to innovating through collaboration, discover where industry changemakers see the strengths of cell and gene in 2024. -
How pharma is unleashing the benefits of real-world evidence along the value chain
Real-world evidence (RWE) is providing a fast track to approval and reimbursement. -
Tackle social determinants of health via data and community engagement
Social determinants of health can blur the safety and efficacy profiles of therapies, making it critical for the pharmaceutical industry to find ways to ease healthcare barriers. -
Transform patient-driven healthcare: Synthesize RWE and AI
The future of healthcare is here, and it's powered by real-world evidence (RWE) and artificial intelligence (AI), transforming patient care and clinical decision-making.
Patients and Medical
-
Digital patient engagement finalists revealed
Finalists for Pharma Awards Europe 2024 have been announced for ‘Most Valuable Digital Patient Engagement’, sponsored by Sciensus. -
Three Pathways to Patient Centricity and Win-Win Stakeholder Outcomes
A round up of a panel discussion at Reuters Events: Pharma 2023, featuring insights from - GSK, Accord Healthcare, Boehringer Ingelheim, CSL Behring, and the Council of Europe -
How to synthesise real-world evidence and AI to transform patient-driven healthcare
Pharmaceutical companies have more real-world data (RWD) than ever -
Revolutionizing Hemophilia Advocacy: Unifying Voices for a Brighter Future
The landscape of hemophilia care has undergone a remarkable transformation in recent decades, marked by momentous advancements in treatment, shifting societal attitudes, and an expanding scope of advocacy efforts. -
Using data to upgrade patient journeys
Collecting and analyzing patient data can improve all aspects of a patient’s health journey. Data privacy must never be compromised in the process.